<DOC>
	<DOC>NCT01955603</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0215-0384 administered to subjects with moderate to severe rheumatoid arthritis (RA) concomitantly treated with methotrexate (MTX).</brief_summary>
	<brief_title>A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Male or female, age between 18 and 75 years (both years inclusive), for Russia only: Age between 1865 years (both years inclusive) Moderate to severe RA, confirmed by a Disease Activity Score based on 28 joints and Creactive protein (DAS28 (CRP)) equal to or above 4.5 and a minimum of five tender and five swollen joints based on a 28 joint count (a joint can score as both tender and swollen) MTX (1025 mg/week both inclusive) for at least 16 weeks, with an unchanged dose for at least 6 weeks prior to screening and until randomisation Females who are not of childbearing potential must have been postmenopausal for at least 1 year confirmed by folliclestimulating hormone (FSH) equal to or above 26.7 U/L or be surgically sterile Past or current inflammatory joint disease other than RA (e.g. gout [crystal proven], psoriatic arthritis, juvenile idiopathic arthritis, reactive arthritis or Lyme disease Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) within 4 weeks prior to randomisation Clinically significant cardiac or cardiovascular disease Past or current malignancy Evaluation of tuberculosis screening indicative of latent or active tuberculosis (TB)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>